Blood Components and What Each One Treats — RBCs, Platelets, Plasma and Cryoprecipitate
One Donation, Multiple Lives
When a person donates blood in Lahore, they give approximately 450 millilitres of whole blood — a mixture of red blood cells, white blood cells, platelets, and plasma all circulating together. In modern transfusion medicine, this whole blood is almost never transfused as a single unit. Instead it is separated into its individual components, each stored under the conditions that preserve its specific function, and each used to treat a specific clinical condition. The result is that a single donation can potentially help two, three, or even four different patients — each receiving precisely the component their condition requires.
Understanding what each blood component is, what it does, and which patients depend on it gives blood donation its full clinical meaning.
Red Blood Cells — Carrying Oxygen to Every Tissue
Red blood cells — RBCs — are the most familiar and most frequently transfused blood component. They are the cells responsible for carrying oxygen from the lungs to every tissue and organ in the body, a function made possible by haemoglobin — the iron-containing protein within each red cell that binds oxygen in the lungs and releases it in the tissues.
When separated from whole blood, red blood cells are suspended in an additive solution that preserves their viability and can be stored at two to six degrees Celsius for up to 42 days. Each unit contains the red cells from one whole blood donation and raises the recipient’s haemoglobin level by approximately one gram per decilitre.
Red blood cell transfusions are given to patients with anaemia severe enough to cause symptoms — breathlessness, chest pain, extreme fatigue, and haemodynamic instability. The most urgent indication is acute haemorrhage — trauma patients, patients bleeding during or after surgery, women haemorrhaging after childbirth, and patients with gastrointestinal bleeding all require red cell transfusions to restore oxygen-carrying capacity rapidly when blood loss has been significant.
Chronic anaemia from conditions including iron deficiency, kidney disease, haematological malignancies, and chemotherapy also requires red cell transfusion when haemoglobin falls below a level at which the body can no longer compensate. Patients with sickle cell disease and thalassaemia major depend on regular red cell transfusions throughout their lives to maintain adequate haemoglobin levels and prevent the crises and organ damage their conditions would otherwise produce without transfusion support.
Red cell compatibility — ABO and Rh blood group matching — is the most critical safety step in transfusion medicine. Transfusing ABO-incompatible red cells causes a severe, potentially fatal haemolytic reaction in which the recipient’s immune system destroys the transfused cells. Every red cell transfusion requires blood group matching and compatibility testing before the unit is released.
Platelets — Controlling Bleeding at the Wound Site
Platelets are tiny cell fragments produced in the bone marrow that play the central role in primary haemostasis — the initial response to vascular injury that forms the platelet plug preventing bleeding at a wound site. When a blood vessel is damaged, platelets rush to the site, adhere to the injured vessel wall, activate, and aggregate into a temporary plug that seals the breach while the clotting cascade forms a more durable fibrin clot around it.
Platelets are the most demanding blood component to store. They must be kept at 20 to 24 degrees Celsius with continuous gentle agitation — cooling damages platelet function and stationary storage causes clumping. Their shelf life is only five to seven days, creating constant pressure on inventory management and making platelets one of the most frequently in short supply of all blood components.
Platelet transfusions are given to patients with severely low platelet counts — thrombocytopaenia — or with platelet function defects that prevent adequate haemostasis despite normal platelet numbers. Chemotherapy and bone marrow transplantation are the most common causes of severe thrombocytopaenia in clinical practice — cancer patients whose bone marrow has been suppressed by treatment produce inadequate platelets and require regular transfusion support to prevent spontaneous bleeding. Patients with aplastic anaemia, leukaemia, and myelodysplastic syndrome also depend on platelet transfusions.
Surgical and trauma patients whose platelet counts fall during massive haemorrhage and resuscitation require platelet transfusions as part of the balanced component replacement strategy that modern massive transfusion protocols prescribe. Patients with inherited platelet function disorders such as Glanzmann thrombasthenia require platelet transfusion during bleeding episodes or before surgical procedures.
Fresh Frozen Plasma — Replacing Clotting Factors
Fresh frozen plasma — FFP — is the liquid component of blood from which red cells and platelets have been separated. It contains all the soluble clotting factors — including the vitamin K-dependent factors II, VII, IX, and X — as well as fibrinogen, albumin, immunoglobulins, and other plasma proteins. Within six to eight hours of donation it is rapidly frozen at minus thirty degrees Celsius or lower, which preserves the labile clotting factors that would otherwise degrade. Stored frozen, FFP remains viable for up to twelve months.
FFP is transfused to patients with multiple clotting factor deficiencies who are actively bleeding or are about to undergo an invasive procedure. Liver disease impairs the synthesis of most clotting factors — patients with cirrhosis or acute liver failure have severely deranged coagulation that requires FFP support during bleeding episodes or before procedures. Warfarin overdose or the need for urgent reversal of anticoagulation in a bleeding patient is treated with FFP when specific reversal agents are unavailable. Disseminated intravascular coagulation — DIC — a catastrophic consumption of clotting factors complicating severe sepsis, obstetric emergencies, and major trauma — requires FFP as a critical component of resuscitation.
Massive transfusion protocols for major trauma and obstetric haemorrhage prescribe FFP alongside red cells in a defined ratio, recognising that large-volume red cell replacement without concurrent clotting factor replacement produces a dilutional coagulopathy that perpetuates bleeding.
Cryoprecipitate — A Concentrated Source of Specific Clotting Factors
Cryoprecipitate is produced by controlled thawing of fresh frozen plasma — when FFP is thawed slowly at two to six degrees Celsius, certain clotting proteins precipitate out of solution and can be separated into a small concentrated volume. This cryoprecipitate is rich in fibrinogen, Factor VIII, von Willebrand factor, Factor XIII, and fibronectin — a specific subset of clotting factors present in much higher concentrations than in an equivalent volume of FFP.
The primary clinical use of cryoprecipitate is fibrinogen replacement. Fibrinogen is the substrate from which fibrin — the structural backbone of a blood clot — is formed. Without adequate fibrinogen, clot formation is impossible regardless of how well other parts of the coagulation cascade function. Severe fibrinogen deficiency occurs in massive haemorrhage with dilutional coagulopathy, DIC, and congenital fibrinogen deficiency. Cryoprecipitate delivers a therapeutic fibrinogen dose in a much smaller volume than would be required using FFP alone — a significant advantage when volume overload is a concern.
Patients with haemophilia A — deficiency of Factor VIII — and von Willebrand disease historically received cryoprecipitate as their primary treatment. Modern practice uses specific factor concentrates where available, but cryoprecipitate remains an important resource when concentrates are unavailable.